Document Detail


Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study.
MedLine Citation:
PMID:  16109055     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to examine efficacy and tolerability of eletriptan in patients switched from barbiturate-containing combinations (Fiorinal), Fioricet. Migraineurs (n = 160) meeting IHS criteria, with unsatisfactory response in the past year to butalbital-containing combinations, treated up to 16 attacks over 3 months with eletriptan 40 mg. Assessments included headache response and pain-free rates and functional impairment at baseline and 2 h postdose, and global ratings of treatment satisfaction at 24 h. At 2 h postdose, average headache response and pain-free rates were 71% (95% CI, 69-74%) and 37% (95% CI, 35-40%), respectively; 68.5% of patients (95% CI, 65-72%) reported functional response. Within-patient analysis found no efficacy diminution over time (no tolerance). Average headache recurrence rate was 20% (95% CI, 18-23%). Eletriptan was well-tolerated; 6 (3.7%) patients discontinued due to adverse events. There were no serious treatment-related adverse events. We conclude that in poor responders to butalbital-caffeine combinations, switching to eletriptan 40 mg was well-tolerated and efficacious.
Authors:
V T Martin; E Loder; K Taylor; M Almas; B Hilliard
Related Documents :
22748865 - Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with int...
16838335 - Duration of vitamin k antagonist therapy for venous thromboembolism: a systematic revie...
22389825 - Safety and efficacy of thrombolytic therapy using rt-pa (alteplase) in acute ischemic s...
22889255 - A preliminary study to assess the efficacy of a new uva1 laser for treatment of psoriasis.
7229645 - Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage...
21712865 - Dexmedetomidine and clonidine in epidural anaesthesia: a comparative evaluation.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cephalalgia : an international journal of headache     Volume:  25     ISSN:  0333-1024     ISO Abbreviation:  Cephalalgia     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-19     Completed Date:  2005-10-12     Revised Date:  2009-10-28    
Medline Journal Info:
Nlm Unique ID:  8200710     Medline TA:  Cephalalgia     Country:  England    
Other Details:
Languages:  eng     Pagination:  726-34     Citation Subset:  IM    
Affiliation:
Division of General Internal Medicine, University of Cincinnati, Cincinnati, OH 452674217, USA. martindoc@pol.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetaminophen / therapeutic use
Adolescent
Adult
Analgesics / therapeutic use*
Aspirin / therapeutic use
Barbiturates / therapeutic use*
Caffeine / therapeutic use
Drug Combinations
Female
Humans
Indoles / therapeutic use*
Male
Middle Aged
Migraine Disorders / drug therapy*
Patient Satisfaction
Pyrrolidines / therapeutic use*
Quality of Life
Serotonin Agonists / therapeutic use*
Treatment Outcome
Tryptamines
Chemical
Reg. No./Substance:
0/Analgesics; 0/Barbiturates; 0/Drug Combinations; 0/Indoles; 0/Pyrrolidines; 0/Serotonin Agonists; 0/Tryptamines; 0/acetaminophen, butalbital, caffeine drug combination; 0/eletriptan; 103-90-2/Acetaminophen; 50-78-2/Aspirin; 51005-25-5/aspirin, butalbital and caffeine drug combination; 58-08-2/Caffeine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--res...
Next Document:  Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing.